Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects

Qiuyi Lv, Yuxin Pan, Xing Chen, Jingpei Wei, Wei Wang, Hua Zhang, Jifeng Wan, Shiqiang Li, Yan Zhuang, Baolin Yang, Dayong Ma, Ren Dawei, Zijun ZhaoFrontiers in Psychiatry 2022 · DOI

TL;DR

This review synthesizes current knowledge on depression in Multiple System Atrophy (MSA), a rare neurodegenerative disease. It highlights that depression is a common and significant comorbidity in MSA patients, impacting their quality of life, and explores its pathological, clinical, and imaging aspects, identifying key areas for future research.

What Problem Does This Paper Address?

Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder affecting autonomic, cerebellar, and pyramidal systems. While known for its motor and autonomic symptoms, MSA patients frequently experience neuropsychiatric disorders, with depression being particularly prevalent. However, the understanding of MSA-related depression is limited, lacking a comprehensive overview of its underlying mechanisms, clinical presentation, and neurobiological correlates. This paper aims to bridge this gap by reviewing existing literature on the pathological, clinical, and imaging aspects of depression in MSA, providing a foundation for further research and clinical attention.

Methods

This paper is a review article that synthesizes existing research. The authors performed focused literature searches using PubMed and Google Scholar from 1980 to January 2022, using keywords related to neuropathology, prevalence, and neuroimaging of depression in MSA. They screened titles and abstracts, then reviewed full-text articles and reference lists to identify relevant original research and review articles. The review then categorizes and discusses the findings based on pathological, clinical, and imaging perspectives.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing literature rather than presenting new experimental data or introducing new datasets.

Key Insights and Ideas

  • Depression is a significant and common comorbidity in MSA: A substantial proportion of MSA patients suffer from depression, often more so than in the general population or even compared to Parkinson's Disease (PD) patients in some studies.
  • Pathological underpinnings are complex: While the exact mechanisms are not fully understood, evidence points to disruptions in neurotransmitter systems (dopamine, norepinephrine, serotonin, acetylcholine), inflammation, oxidative stress, and potentially neurotrophic factor dysregulation as contributing factors to depression in MSA.
  • Clinical presentation varies, but impacts quality of life: Depression in MSA is not just a symptom but a significant predictor of reduced health-related quality of life (HrQoL), often independent of disease severity.
  • Subtype differences are debated: While some studies suggest no significant difference in depression prevalence between the parkinsonian (MSA-P) and cerebellar (MSA-C) subtypes, others indicate MSA-P might have a higher burden, though this remains controversial.
  • Neuroimaging offers clues but is sparse: Current neuroimaging studies are limited but suggest potential involvement of the amygdala and its connectivity with other brain regions (e.g., frontal cortex) in MSA-related depression.
  • Assessment tools matter: The choice of depression assessment scale can significantly influence reported prevalence rates, highlighting the need for standardized and consistent methodologies in future research.

Key Results

  • Prevalence: More than 50% of MSA patients suffer from depression, with ~10.4-46.3% experiencing moderate to severe depressive symptoms.
  • Comparison to other conditions: MSA patients generally show higher rates of depression compared to healthy controls and, in many studies, compared to Parkinson's Disease (PD) patients. However, comparisons with Progressive Supranuclear Palsy (PSP) are less consistent, with some studies suggesting PSP patients may have more depression.
  • Impact on Quality of Life: Depression is consistently identified as an independent and important predictor of poor health-related quality of life (HrQoL) in MSA patients.
  • Gender and Duration: Female patients, those with longer disease duration, and those with more severe disease conditions tend to have a higher prevalence and severity of depression.
  • Neuroimaging findings (limited): Pilot studies suggest metabolic decreases in certain brain regions (frontal, parietal, cerebellar cortex, putamen) are associated with depression severity in MSA. Abnormal amygdala-cortical functional connectivity has also been observed in depressed MSA patients.

Limitations and Future Work

  • Limited Neuroimaging Data: The authors acknowledge that available neuroimaging studies are sparse, making it difficult to draw definitive conclusions about the radiological aspects of depression in MSA. More sophisticated neuroimaging techniques are needed.
  • Controversial Subtype Differences: Disagreement exists regarding whether depression prevalence differs between MSA-P and MSA-C subtypes, necessitating further research to reconcile these findings.
  • Scale Variability: The use of different depression assessment scales across studies makes direct comparison challenging and can lead to conflicting results.
  • Mechanistic Understanding: While pathological factors are discussed, the exact mechanisms underlying MSA-related depression remain unclear, calling for more mechanistic studies, including those using animal models.
  • Treatment Gaps: The paper notes a lack of large-scale randomized controlled trials (RCTs) for treating depression in MSA, highlighting the need for research into effective pharmacological and non-pharmacological interventions.
  • Gut-Brain Axis: The emerging role of the gut-brain axis and its potential influence on inflammatory conditions in MSA warrants further investigation.
  • Clinical Assessment: The authors emphasize the importance of screening for depression as part of routine clinical assessment for MSA patients, particularly for vulnerable groups (females, those with longer disease duration, etc.).

Summary updated

Abstract

Multiple system atrophy (MSA) is a common atypical parkinsonism, characterized by a varying combination of autonomic, cerebellar, and pyramidal systems. It has been noticed that the patients with MSA can be accompanied by some neuropsychiatric disorders, in particular depression. However, there is limited understanding of MSA-related depression. To bridge existing gaps, we summarized research progress on this topic and provided a new perspective regarding pathological, clinical, and imaging aspects. Firstly, we synthesized corresponding studies in order to investigate the relationship between depression and MSA from a pathological perspective. And then, from a clinical perspective, we focused on the prevalence of depression in MS patients and the comparison with other populations. Furthermore, the associations between depression and some clinical characteristics, such as life quality and gender, have been reported. The available neuroimaging studies were too sparse to draw conclusions about the radiological aspect of depression in MSA patients but we still described them in the presence of paper. Finally, we discussed some limitations and shortcomings existing in the included studies, which call for more high-quality basic research and clinical research in this field.
BibTeX
@inproceedings{lv2022depression,
  author = {Qiuyi Lv and Yuxin Pan and Xing Chen and Jingpei Wei and Wei Wang and Hua Zhang and Jifeng Wan and Shiqiang Li and Yan Zhuang and Baolin Yang and Dayong Ma and Ren Dawei and Zijun Zhao},
  title = {{Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects}},
  booktitle = {Frontiers in Psychiatry},
  year = {2022},
  doi = {10.3389/fpsyt.2022.980371},
}
Figure